<DOC>
	<DOCNO>NCT01407978</DOCNO>
	<brief_summary>This single-blind , reference drug control study ass safety tolerability FLUVAL P H1N1 monovalent influenza vaccine ( whole virus , inactivate , adjuvanted alumn phosphate gel ) contain 6 mcgHA per 0.5mL active ingredient child adolescent . To assess , secondary objective , efficacy ( immunogenicity ) vaccine serology test .</brief_summary>
	<brief_title>Tolerability Immunogenicity Study FLUVAL P H1N1 Flu Vaccine Omninvest Children Adolescents</brief_title>
	<detailed_description>Primary Objective : - To assess tolerability/safety ( incidence adverse event 21-28 day follow vaccination ) study drug . Secondary Objectives : - To assess efficacy ( immunogenicity ) study drug serology test blood sample take Day 21‑28 immunization group age group . - To assess long term ( 180-210 day follow vaccination ) tolerability/safety ( incidence adverse event ) study drug .</detailed_description>
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Aluminum phosphate</mesh_term>
	<criteria>Children age 3 12 year , adolescent age 12 18 year , sex ; Are good health ( determine vital sign exist medical condition ) stable medical condition . Subjects exclude know adequately treat clinically significant organ systemic disease ( e.g . asthma diabetes ) , opinion investigator , significance disease compromise subject 's participation study . Female volunteer childbearing potential negative result urine pregnancy test prior vaccination agree use acceptable contraception method ( include implant , injectibles , combine oral contraceptive , effective intrauterine device /IUDs/ , sexual abstinence , vasectomized partner ) abstinence throughout trial become pregnant duration study . Capability adolescent participant age 12 18 year legitimate representative volunteer understand comply plan study procedure ; Absence existence exclusion criterion . Pregnancy breast feed positive urine pregnancy test baseline prior vaccination ; Known allergy egg component vaccine ( particular mercury ) ; History GuillainBarré syndrome ; Active neoplasm ( i.e . require form antineoplastic therapy ) ; Immunosuppressive therapy precede 36 month ; Concomitant corticosteroid therapy , include highdose inhaled corticosteroid ( local corticosteroid corticosteroid nasal spray permit ) ; Immunoglobulin ( similar blood product ) therapy within 3 month prior vaccination ; Documented HIV , HBV HCV infection ; Chronic illness , opinion investigator , may interfere evaluation immunoresponse ; Acute febrile respiratory illness within one week prior vaccination ; Vaccine therapy within 4 week prior vaccination ; Influenza vaccination within 6 month prior vaccination ; Experimental drug therapy within 1 month prior vaccination ; Past current psychiatric disease volunteer legitimate representative upon judgement investigator may effect objective decisionmaking volunteer legitimate representative ; Alcohol drug abuse participant legitimate representative .</criteria>
	<gender>All</gender>
	<minimum_age>3 Years</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>Influenza</keyword>
	<keyword>Pandemic vaccine</keyword>
	<keyword>Seasonal vaccine</keyword>
	<keyword>Prevention</keyword>
	<keyword>Influenza vaccine</keyword>
	<keyword>Influenza human</keyword>
	<keyword>Pandemic influenza human</keyword>
	<keyword>Influenza vaccine child</keyword>
	<keyword>Influenza vaccine adolescent</keyword>
	<keyword>Seasonal vaccine child</keyword>
	<keyword>Seasonal vaccine adolescent</keyword>
</DOC>